TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ZyVersa Therapeutics ( (ZVSA) ) has provided an announcement.
On June 24, 2025, ZyVersa Therapeutics entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, allowing the sale of up to $10 million in common stock over two years. This agreement aims to provide flexible funding to advance the clinical development of ZyVersa’s Cholesterol Efflux Mediator™ VAR 200 for chronic kidney diseases, potentially impacting the company’s market positioning in the growing global kidney disease drug market.
The most recent analyst rating on (ZVSA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ZyVersa Therapeutics stock, see the ZVSA Stock Forecast page.
Spark’s Take on ZVSA Stock
According to Spark, TipRanks’ AI Analyst, ZVSA is a Underperform.
ZyVersa Therapeutics faces significant financial challenges with no revenue and ongoing losses. Technical indicators show bearish momentum, and the negative P/E ratio suggests overvaluation concerns. The lack of dividend yield further limits investment appeal.
To see Spark’s full report on ZVSA stock, click here.
More about ZyVersa Therapeutics
ZyVersa Therapeutics, Inc. is a clinical stage specialty biopharmaceutical company that develops first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The company is advancing a therapeutic development pipeline with proprietary technologies, including Cholesterol Efflux Mediator™ VAR 200 for kidney diseases and Inflammasome ASC Inhibitor IC 100 for inflammatory diseases.
Average Trading Volume: 3,776,741
Technical Sentiment Signal: Sell
Current Market Cap: $2.97M
See more insights into ZVSA stock on TipRanks’ Stock Analysis page.